prijava
SARAJEVO, January 28 (FENA) - The largest domestic pharmaceutical company Bosnalijek Sarajevo has successfully completed the EU GMP certification process for the production of new plant of liquid and semi-solid pharmaceuticals, which opened last year.
In this way, it was ensured that the full capacity of the newly opened facility could be fully utilized, in the construction of which KM 50 million was invested, and whose maximum annual production volume was 34 million packages of liquid and semi-solid forms of medicines, which is a fivefold increase over existing capacities.
With the successful certification of the new plant, the entire production process at Bosnalijek is in line with the rules and guidelines of the EU GMP, which means that all the products can be placed on the European Union market.
General Manager of Bosnalijek Nedim Uzunović points out that by obtaining this certificate, it has once again been confirmed that all processes within the company comply with the best world practices and standards, and that all Bosnalijek products are of the highest quality.
“Our top priority is to fulfill the highest expectations of the users of our products, which we ensure through the production of medicaments of high efficiency, safety and quality, which was once again confirmed by obtaining this certificate,” said Uzunović.
He stressed that the strategic commitment of this company is to open new export markets, and that all prerequisites necessary for export to all countries of the European Union have now been created when it comes to their products, but also when it comes to contract production and cooperation with large world pharmaceutical companies.
“We are proud that Bosnalijek is one of the leading exporters in BiH, and when it comes to medicament production, it is also the largest. Half a billion KM worth of exports over the past five years, with the continued increase in the value of exports every year, is the best indicator,” Uzunović added.
After successfully obtaining EU GMP certification, Bosnalijek is also ready to initiate the process of obtaining the necessary approvals from the US FDA, based on the Mutual Recognition Agreement for human drug manufacturing facilities between the USA and the EU, thereby creating the conditions for meeting the formal requirements for exports, not only to the United States, but to every country in the world, it is stated from Bosnalijek.
(FENA) A. B.
